Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Olutasidenib

Olutasidenib Phase 1/2 (glioma cohort)

Rigel · Phase 1/2 · Completed · Enrollment 93

NCT03684811

ArmReported safety
Olutasidenib 150 mg BIDgrade 3 to 4 ALT increase: 12%grade 3 to 4 AST increase: 12%

A count stays a count. This page does not turn a count into a percent.